findmyKOL
Clinical trialNCT05363280RecruitingPhase 2Interventional

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

SponsorAdvenchen Pharmaceuticals, LLC.Enrollment80Non-Small Cell LungRenal Cell Carcinoma (RCC)Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Spain
  • Hospital Universitari Vall D'Hebron

    Barcelona, Spain

    Pedro Filipe Simoees Da Rocha, MD
    Recruiting
  • Hospital Universitario Ramón Y Cajal

    Madrid, Spain

    María Eugenia Olmedo García, MD
    Recruiting
United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

    Aakash Desai, MD
    Recruiting
  • Cleveland Clinic Florida

    Weston, Florida, United States

    Withdrawn
  • Northwestern University

    Chicago, Illinois, United States

    Completed
  • Siteman Cancer Center, Washington University

    St Louis, Missouri, United States

    Saiama Waqar, MD
    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Lukas Delasos, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AL8326 40 mgAL8326 60 mgAL8326 80 mg--stopped
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Nov 2022
Primary completion
31 Dec 2027
Completion
31 Dec 2028
Last update posted
8 May 2026
Registered enrollment
80
Registry id
NCT05363280
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.